Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of eptinezumab (Vyepti) in pediatric migraine (REJOIN)
2022-502917-27-00Phase 3Authorised
- Sponsor
- Lundbeck
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of eptinezumab in migraine, sponsored by Lundbeck. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events. Planned start Apr 2024; status: authorised.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2022-502917-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502917-27-00.